How Can Stakeholders Collaborate to Create a Patient-Centric Health Care System?

Luis Torres, MBA, Vice President, Managed Care, BioPlus Specialty Pharmacy, discusses how collaboration between health care stakeholders is necessary to further the push towards a system that revolves around the patient.

Transcript: “One of my mantras is that the patient is at the center of everything we do, and all of us—patient provider, plan sponsor, PBM, health plan consultant—we really are all in the patient care business. So, if we begin with the patient in the center of every initiative, every objective, every clinical protocol and program, how do we help the patient better manage the medication? At the end of the day, the patient is looking for solutions and answers and ways to better manage what’s already typically, when dealing with specialty medication, something quite complex, and if we can together have a true medium and fluid medium of exchange within a platform, whether it be a patient centered medical home, whether it be a collaborative panel that acts actually as a PNT committee, and looking at both sides of the equation because you also have the medical side and the pharmacy side. Often times they don’t speak to one another, so how do we work together to create kind of that bridge where everything that we’re doing is were managing the patient at the provider level and the continuity of care with the plan sponsor and the specialty provider as well in order to provide optimal outcomes for the patient at the end of the day?”

Most Popular

Related Articles

A data-centric approach is vital for patients with complex conditions, particularly in determining what has worked well and anticipating what medical or pharmacy care is required for effective outcomes in the future.
The shift from fee-based, volume-driven care to value-based, patient-centered care and the growth of specialty pharmaceuticals are propelling us all into uncharted territory, no matter what role you play in health care.
Failure to recognize the interests of manufacturers to ensure proper use of 340B pricing may result in 340B hospitals missing the opportunity to secure and retain discounts on key orphan and specialty drugs or may render them unable to access the drugs at all.
Company Profile >
Industry Guide >
Market News >
Peer Exchange >
Conferences >
Subscribe >
Specialty Times Resources
About Us
Contact Us
Terms & Conditions
MJH Associates >
Pharmacy Times
American Journal of Managed Care
MD Magazine
Targeted Oncology
Physicians' Education Resource
Pharmacy & Healthcare Communications, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747

Copyright Specialty Pharmacy Times 2006-2018
Pharmacy & Healthcare Communications, LLC. All Rights Reserved.